This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Bristol Myers Squibb Co. (BMY) shed 1.44% to $57.38 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&amp;P 500 Index falling 0.41% to 7,200.75 and Dow Jones Industrial Average falling 1.13% to 48,941.90.
This was the stock's second consecutive day of losses.
Bristol Myers Squibb Co. closed 8.76% below its 52-week high of $62.89, which the company achieved on March 2nd.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson &amp; Johnson (JNJ) fell 1.32% to $224.20, Pfizer Inc. (PFE) fell 0.11% to $26.30, and Abbott Laboratories (ABT) fell 2.15% to $87.54.
Data source: Dow Jones Market Data, FactSet. Data compiled May 4, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-04-26 1637ET

Bristol Myers Squibb Co. (BMY) shares fell 1.44% to $57.38 on Monday, marking its second consecutive day of losses. The stock is now 8.76% below its 52-week high of $62.89. In comparison, competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories also experienced declines. The S&P 500 Index and Dow Jones Industrial Average fell by 0.41% and 1.13%, respectively, indicating a poor trading session overall.

MarketWatch Automated

Bristol Myers Squibb

iShares Global Healthcare

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VG Health

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

Direxion Pharma & Medical Bull 3X

Invesco Nasdaq Biotechnology ETF

ProShares Ultra Health Care ETF

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Pfizer

Abbott Laboratories

Factset Research

Bristol-Myers Squibb Company

Bristol Myers Squibb Co. Stock Underperforms Monday When Compared To Competitors